Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4 for PI3Kβ, and 6.7 for PI3Kα. This compound is utilized in researching chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4 for PI3Kβ, and 6.7 for PI3Kα. This compound is utilized in researching chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD) [1]. |
Targets&IC50 | PI3Kδ:8.0 (pKi), PI3Kγ:6.5 (pKi), PI3Kβ:6.4 (pKi), PI3Kδ:5.8 (pIC50), PI3Kα:6.7 (pKi) |
Molecular Weight | 444.27 |
Formula | C20H15Cl2N5O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PI3Kδ-IN-12 PI3K/Akt/mTOR signaling PI3K inhibitor inhibit